Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caribou Biosciences Inc (NQ: CRBU )

2.270 -0.130 (-5.42%)
Streaming Delayed Price Updated: 2:41 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,047,939
Open 2.380
Bid (Size) 2.260 (51)
Ask (Size) 2.270 (14)
Prev. Close 2.400
Today's Range 2.265 - 2.490
52wk Range 1.500 - 8.330
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evaluating Caribou Biosciences: Insights From 4 Financial Analysts
Via Benzinga
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-59.25%
-59.25%
1 Month
+21.39%
+21.39%
3 Month
-42.96%
-42.96%
6 Month
-57.09%
-57.09%
1 Year
-65.86%
-65.86%

More News

Read More
Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Expert Ratings For Caribou Biosciences
Via Benzinga
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Attention Biotech Investors - Stocks To Watch
Via Benzinga
3 Underappreciated Stocks That Could 10x in 10 Years
Via InvestorPlace
CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Caribou Biosciences, Inc.
Via GlobeNewswire
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
From Caribou Biosciences, Inc.
Via GlobeNewswire
Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Gold Down Over 1%; ClearOne Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Caribou Biosciences Stock Is Crashing Today
Via The Motley Fool
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Via Talk Markets
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.